4.7 Article

Serum neurofilament light chain as outcome marker for intensive care unit patients

Journal

JOURNAL OF NEUROLOGY
Volume 268, Issue 4, Pages 1323-1329

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00415-020-10277-9

Keywords

Neurofilament; Intensive care unit; Outcome; Critical illness polyneuromyopathy

Funding

  1. Georgius Agricola Stiftung Ruhr, Bochum, Germany
  2. Projekt DEAL

Ask authors/readers for more resources

This study found that serum NfL levels could potentially serve as a biomarker for predicting outcomes of ICU patients, especially for those with central nervous system impairment.
Objective Neurofilament light chain (NfL) in serum indicates neuro-axonal damage in diseases of the central and peripheral nervous system. Reliable markers to enable early estimation of clinical outcome of intensive care unit (ICU) patients are lacking. The aim of this study was to investigate, whether serum NfL levels are a possible biomarker for prediction of outcome of ICU patients. Methods Thirty five patients were prospectively examined from admission to ICU until discharge from the hospital or death. NfL levels were measured longitudinally by a Simoa assay. Results NfL was elevated in all ICU patients and reached its maximum at day 35 of ICU treatment. Outcome determined by modified Rankin Scale at the end of the follow-up period correlated with NfL level at admission, especially in the group of patients with impairment of the central nervous system (n = 25, r = 0.56, p = 0.02). Conclusion NfL could be used as a prognostic marker for outcome of ICU patients, especially in patients with impairment of the central nervous system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Serum neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes

Melissa Amrein, Stephanie Meier, Ibrahim Schafer, Sabine Schaedelin, Eline Willemse, Pascal Benkert, Joan Walter, Christian Puelacher, Tobias Zimmermann, Daniela Median, Caroline Egli, David Leppert, Raphael Twerenbold, Michael Zellweger, Jens Kuhle, Christian Mueller

Summary: sNfL concentration is not a reliable diagnostic biomarker for fCAD, but it can predict adverse cardiovascular outcomes, including all-cause death, cardiovascular death, and stroke/TIA.

BIOMARKERS (2023)

Article Medical Laboratory Technology

Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood

Ulf Andreasson, Johan Gobom, Vincent Delatour, Guy Auclair, Yoav Noam, Stephen Lee, Jason Wen, Andreas Jeromin, Burak Arslan, Aleksandra Maceski, Eline Willemse, Henrik Zetterberg, Jens Kuhle, Kaj Blennow

Summary: This study determined the best certified reference material (CRM) for neurofilament light chain (NfL) in blood by analyzing 40 paired serum and plasma samples. The results showed that using cerebrospinal fluid (CSF) for sample validation was more accurate than using recombinant human NfL protein, and serum was a better choice than plasma as the matrix for a CRM.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients

Alexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, Alessandro Cagol, Reza Rahmanzadeh, Riccardo Galbusera, Po-Jui Lu, Matthias Weigel, Esther Ruberte, Ernst-Wilhelm Radue, Sabine Schaedelin, Pascal Benkert, Yaldizli Oezguer, Tim Sinnecker, Stefanie Mueller, Lutz Achtnichts, Jochen Vehoff, Giulio Disanto, Oliver Findling, Andrew Chan, Anke Salmen, Caroline Pot, Patrice Lalive, Claire Bridel, Chiara Zecca, Tobias Derfuss, Luca Remonda, Franca Wagner, Maria Vargas, Renaud Du Pasquier, Emanuele Pravata, Johannes Weber, Claudio Gobbi, David Leppert, Jens Wuerfel, Tobias Kober, Benedicte Marechal, Ricardo Corredor-Jerez, Marios Psychogios, Johanna Lieb, Ludwig Kappos, Meritxell Bach Cuadra, Jens Kuhle, Cristina Granziera

Summary: This study evaluated the accuracy of LeMan-PV software for detecting new and enlarged white matter lesions in multiple sclerosis patients. The results showed that LeMan-PV had similar sensitivity in detecting new lesions compared to other recent studies using neural networks. Although its performance is not optimal, the main advantage of LeMan-PV is that it provides automated clinical decision support integrated into the routine radiological workflow.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2023)

Article Clinical Neurology

Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis

Alessandro Cagol, Nuria Cerda Fuertes, Marc Stoessel, Muhamed Barakovic, Sabine Schaedelin, Marcus D'Souza, Jens Wurfel, Alexander U. Brandt, Ludwig Kappos, Till Sprenger, Yvonne Naegelin, Jens Kuhle, Cristina Granziera, Athina Papadopoulou

Summary: This study investigated the associations among OCT changes, MRI measurements of brain volume loss, and physical and cognitive impairment in patients with multiple sclerosis. The results showed that OCT measures of pRNFL and GCIPL were associated with volumes of gray matter structures, and inversely correlated with T2-lesion volume. These findings highlight the value of OCT as markers of neurodegeneration and disability in multiple sclerosis.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus

Nils G. Margraf, Justina Dargvainiene, Emily Theel, Frank Leypoldt, Wolfgang Lieb, Andre Franke, Klaus Berger, Jens Kuhle, Gregor Kuhlenbaeumer

Summary: This study investigates the potential of neurofilament light chain (NfL) in serum and cerebrospinal fluid as a biomarker for neurodestruction in status epilepticus. The results suggest that the concentration of NfL is mainly determined by the duration of status epilepticus, rather than the type of status or treatment refractoriness.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience

Valentin Loser, Pascal Benkert, Alex Vicino, Pansy Lim Dubois Ferriere, Thierry Kuntzer, Jerome Pasquier, Aleksandra Maceski, Jens Kuhle, Marie Theaudin

Summary: Serum neurofilament light chain (sNfL) may serve as an early and reliable biomarker of peripheral neuropathy in hATTR amyloidosis, allowing for assessment of disease severity and treatment response.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2023)

Article Clinical Neurology

Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis

Charidimos Tsagkas, Antal Huck-Horvath, Alessandro Cagol, Tanja Haas, Muhamed Barakovic, Michael Amann, Esther Ruberte, Lester Melie-Garcia, Matthias Weigel, Simon Pezold, Regina Schlaeger, Jens Kuhle, Till Sprenger, Ludwig Kappos, Oliver Bieri, Philippe Cattin, Cristina Granziera, Katrin Parmar

Summary: Spinal cord atrophy of the cervical anterior horn is clinically relevant in multiple sclerosis (MS) patients, particularly in progressive MS (PMS) patients and at the level of cervical SC enlargement.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L. Arnold, Andreea M. Rawlings, Svend S. Geertsen, Alex L. Lublin, Stephane Saubadu, Philippe Truffinet, Ludwig Kappos

Summary: The TERIKIDS study demonstrated that teriflunomide is effective and safe in children with relapsing multiple sclerosis (RMS). Teriflunomide treatment is associated with significantly reduced pNfL levels in children with RMS.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Multidisciplinary Sciences

Propionate exerts neuroprotective and neuroregenerative effects in the peripheral nervous system

Thomas Grueter, Nuwin Mohamad, Niklas Rilke, Alina Blusch, Melissa Sgodzai, Seray Demir, Xiomara Pedreiturria, Katharina Lemhoefer, Barbara Gisevius, Aiden Haghikia, Anna Lena Fisse, Jeremias Motte, Ralf Gold, Kalliopi Pitarokoili

Summary: In inflammatory neuropathies, treatment with propionate showed immunoregulatory and neuroprotective effects. Activation of FFAR3 and histone acetylation resulted in increased resistance to oxidative stress and enhanced neuroregeneration. This pathway provides potential neuroprotection and neuroregeneration for patients with immune-mediated neuropathies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Review Clinical Neurology

Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Xavier Montalban, Paul M. Matthews, Alex Simpson, John L. Petrie, Cormac Sammon, Sreeram Ramagopalan, Giulio Disanto, Jens Kuhle

Summary: Across its clinical development program, ocrelizumab has demonstrated efficacy in improving clinical outcomes in multiple sclerosis. This study systematically collected real-world clinical effectiveness data for ocrelizumab, which consistently showed favorable results, similar to those reported in clinical trials. Initial real-world effectiveness data for ocrelizumab are promising and provide an efficacious treatment option for multiple sclerosis.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Pediatrics

Neurofilament Light Chain serum levels after Hypoxia-Ischemia in a newborn piglet model

Kasper Jacobsen Kyng, Sven Wellmann, Verena Lehnerer, Laerke Hjollund Hansen, Jens Kuhle, Tine Brink Henriksen

Summary: This study investigated the changes of neurofilament light chain (NfL), a potential biomarker for brain injury, in a newborn piglet model of hypoxic-ischemic encephalopathy (HIE). The results showed an increase in NfL levels after hypoxia-ischemia (HI), with the highest values observed at 72 hours post-HI. NfL at 72 hours had high sensitivity and specificity for predicting moderate-severe brain injury.

FRONTIERS IN PEDIATRICS (2023)

Article Health Care Sciences & Services

Individual Concepts in Foot Surgery: A Comparison of Xenogeneic and Autologous Bone Grafts Used in Adults for Lateral Calcaneus-Lengthening Osteotomy According to Evans

Markus Siegel, Lisa Bode, Leonard Simon Brandenburg, Andreas Frodl, Hagen Schmal, Jan Kuehle

Summary: This study retrospectively analyzed 31 adult patients to examine the use and effects of autologous and xenogeneic bone grafts in foot surgery. The results showed that although xenogeneic grafts had a lower incorporation rate, they did not increase the risk of hindfoot alignment loss in the first six months after surgery.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Article Clinical Neurology

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis

Arabella Buchmann, Lukas Pirpamer, Daniela Pinter, Margarete Voortman, Birgit Helmlinger, Alexander Pichler, Aleksandra Maleska Maceski, Pascal Benkert, Gerhard Bachmaier, Stefan Ropele, Markus Reindl, David Leppert, Jens Kuhle, Christian Enzinger, Michael Khalil

Summary: This study findings suggest that elevated levels of sNfL have a significant impact on brain volume changes and can indicate disease progression in pwMS over a short-term period.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Association of serum neurofilament light with microglial activation in multiple sclerosis

Maija Saraste, Markus Matilainen, Anna Vuorimaa, Sini Laaksonen, Marcus Sucksdorff, David Leppert, Jens Kuhle, Laura Airas

Summary: This study found an association between serum neurofilament light (sNfL) and microglial activation in the brain of multiple sclerosis (MS) patients, as measured by TSPO-PET. Increased sNfL levels were correlated with a higher number and larger volume of TSPO-PET-detectable active lesions at the plaque edge and perilesional normal appearing white matter. These findings emphasize the significance of smouldering inflammation and rim-active lesions in promoting neuroaxonal damage and disease progression in MS.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J. Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D'hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivino, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A. Hardy, Danny Decoo, Angel Perez Sempere, Deborah Field, Ray Wynford-Thomas, Nick G. Cunniffe, Izanne Roos, Charles B. Malpas, Alasdair J. Coles, Tomas Kalincik, J. William L. Brown, MSBase Study Grp

Summary: This study found that early non-disabling relapses in people with RRMS are associated with a higher risk of disability accumulation, which may be mitigated by high-efficacy DMTs. Therefore, treatment decisions should take into account the impact of non-disabling relapses.

MULTIPLE SCLEROSIS JOURNAL (2023)

No Data Available